Welcome to our dedicated page for Shuttle Pharmaceuticals Holdings SEC filings (Ticker: SHPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Shuttle Pharmaceuticals Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Shuttle Pharmaceuticals Holdings's regulatory disclosures and financial reporting.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) filed an initial Form 3 reporting that Adam V. Chambers is a director as of 09/08/2025. The filing lists Mr. Chambers' business address in Gaithersburg, MD and indicates he directly beneficially owns 0 shares of the issuer's common stock and holds no derivative securities. The form is an initial disclosure of a director's ownership and contains no reported holdings or exercisable awards.
Shuttle Pharmaceuticals Holdings, Inc. reported that its Board of Directors appointed Adam Chambers as a director effective September 8, 2025. Mr. Chambers is the principal of Bowery Consulting Group Inc., which is the lender under the Company’s revolving loan agreement dated February 28, 2025, and also a party to a consulting services agreement dated March 21, 2025. The Company states there are no family relationships between Mr. Chambers and any of its directors or executive officers, and, other than the loan and consulting agreements, he has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K. The filing also notes there were no arrangements or understandings by which he was appointed to the Board.
Shuttle Pharmaceuticals Holdings, Inc. reported that Steven Richards resigned as a director of the company on August 31, 2025. The company stated that Mr. Richards’ resignation was not due to any disagreements with Shuttle Pharmaceuticals regarding its operations, policies, or practices. The report was signed on behalf of the company by Interim Chief Executive Officer Christopher Cooper.
Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G reporting shared beneficial ownership of 56,237 shares of Shuttle Pharmaceuticals Holdings, Inc. common stock, representing 4.99% of the class. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and pursuant to an investment management agreement exercises voting and investment power over those securities. Mr. Boyd, as managing member of Armistice Capital, is reported with the same shared voting and dispositive power. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control.
Steven M. Richards, a director of Shuttle Pharmaceuticals Holdings (SHPH), was granted 29,240 Restricted Stock Units (RSUs) on 08/08/2025, as reported on a Form 4 signed 08/12/2025. The filing states each RSU represents the contingent right to receive one share of common stock at no cash price.
One-third of the RSUs will vest on each of 08/08/2026, 08/08/2027 and 08/08/2028, meaning the award converts into a total of 29,240 shares if all vest according to the stated schedule. The Form 4 lists the ownership form as direct and shows the grant was reported under a non-cash equity award.
Shuttle Pharmaceuticals director Oleh Nabyt was granted 29,240 restricted stock units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock and is reported with a $0 price. The RSUs vest in three equal installments: one-third on 08/08/2026, one-third on 08/08/2027 and one-third on 08/08/2028. The award is reported as a direct beneficial holding and, if fully vested and converted, would result in receipt of up to 29,240 shares of common stock.
George Scorsis, a director of Shuttle Pharmaceuticals Holdings (SHPH), was granted 29,240 Restricted Stock Units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock. The award is reported as direct beneficial ownership by the reporting person.
One-third of the RSUs vest on each of 08/08/2026, 08/08/2027 and 08/08/2028, meaning up to 29,240 common shares may be issued to satisfy the award over three years if vesting conditions are met. The grant is a standard equity compensation award for a board member with a multi-year retention schedule.
Joseph Tung, a director of Shuttle Pharmaceuticals Holdings (SHPH), was granted 29,240 restricted stock units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock and the award was recorded at $0. The RSUs vest in three equal installments, with one-third vesting on each of 08/08/2026, 08/08/2027 and 08/08/2028, and the reported ownership form is direct. Following this reported transaction, the RSUs correspond to 29,240 underlying shares.
The filing discloses an equity award that aligns a director with shareholder interests via long-term vesting, but it does not provide the company’s total outstanding share count or other compensation terms needed to assess dilution or material financial impact.
Timothy J. Lorber, Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc. (SHPH), was granted a total of 54,094 restricted stock units (RSUs) in transactions dated 08/08/2025. Each RSU represents a contingent right to receive one share of common stock and the grants were reported on a Section 16 Form 4.
The awards are split into two grants: 29,240 RSUs that vest one-third on each of 08/08/2026, 08/08/2027 and 08/08/2028, and 24,854 RSUs that vest on 02/08/2026. Both grants show an acquisition price of $0 and are held in a direct ownership form.
Shuttle Pharmaceuticals (SHPH) reported continued development-stage operations with no revenue and a six-month net loss of $6,759,472. Cash and cash equivalents rose to $4,817,672 at June 30, 2025 from $1,920,144 at year-end 2024, driven by net financing proceeds of approximately $8.78 million. Total assets were $5.50 million and stockholders' equity increased to $3.61 million as shares outstanding expanded to 1,070,773.
The company disclosed a substantial doubt about its ability to continue as a going concern: management states existing cash, equity proceeds and an undrawn $2.0 million revolving note are not expected to fund operations and clinical trials through the next 12 months. Material items include reverse stock splits to meet Nasdaq requirements, equity financings in March and June 2025, accelerated stock-based compensation of about $0.5 million from RSU modifications, and a $2.0 million payment to an IR agency recorded as expense.